At FidoCure®, we have created a platform which integrates diagnostic testing and the sequencing of canine tumor DNA, with access to targeted therapy using small molecule inhibitors.
This has enabled us to collect outcome data to complete the “circle of information.”
In brief the poster covered:
There are a few conclusions to this study.
First, that real world data, data from the medical records of dogs, can be used to assess the tolerability and safety of therapeutics.
Second, the majority of the small molecule inhibitors that we evaluated had a safety profile that was comparable to those reported for Palladia. We are currently enhancing our platform to capture both clinical and clinicopathologic AEs according to the VCOG-CTCAE criteria.
In addition, FidoCure® has partnered with CSU for a study evaluating the efficacy of targeted therapies selected by FidoCure on cell lines from 10 types of canine cancers. This information will help inform the most effective dosages and identify potential biomarkers that make certain cancers more responsive to these drugs.
We would like to send a heartfelt thank you to the Veterinary Cancer Society, all of the veterinary oncologists, and team members who made this study possible.